1 Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience

3 Authors:

2

- 4 Erin M. Wilfong, M.D., Ph.D. 1,21, ORCID ID 0000-0002-6584-1578
- 5 Jennifer J. Young-Glazer, M.D., M.S.C.I², ORCID ID 0000-0002-3265-9112
- 6 Bret K. Sohn, MD²
- 7 Gabriel Schroeder, M.D.³
- 8 Narender Annapureddy, M.D.², ORCID ID 0000-0002-4012-3406
- 9 Erin A. Gillaspie, M.D.⁴, ORCID ID 0000-0003-2075-5534
- 10 April Barnado, M.D., M.S.C.I.², ORCID ID 0000-0002-9573-4335
- 11 Leslie J. Crofford, M.D.², ORCID ID 0000-0002-6347-5738
- 12 Rosemarie Beckford Dudenhofer, M.D.¹

14 Affiliations:

13

- 15 Vanderbilt University Medical Center, Department of Medicine, Division of Allergy, Pulmonary, and
- 16 Critical Care Medicine, Nashville, TN, 37232, USA
- ²Vanderbilt University Medical Center, Department of Medicine, Division Rheumatology and
- 18 Immunology, Nashville, TN, 37232, USA
- ³Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, 37232, USA
- ⁴Vanderbilt University Medical Center, Department of Thoracic Surgery, Nashville, TN 37232
- [†]Corresponding Author:
- 23 Erin M. Wilfong, M.D., Ph.D.
- 24 1161 21st Ave So., MCN T-1218
- Nashville, TN 37232
- 26 Phone: (615) 936-5747

27 Fax: (615) 322-6248

28 Email: erin.m.wilfong@vumc.org

- 29 Abstract:
- 30 **Background**: Recognition of Anti tRNA synthetase (ARS) related interstitial lung disease (ILD) is key
- 31 to ensuring patients have prompt access to immunosuppressive therapies. The purpose of this
- retrospective cohort study was to identify factors that may delay recognition of ARS-ILD.
- 33 **Methods:** Patients seen at Vanderbilt University Medical Center (VUMC) between 9/17/2017-
- 34 10/31/2018 were included in this observational cohort. Clinical and laboratory features were obtained
- via chart abstraction. Kruskal-Wallis ANOVA, Mann-Whitney U, and Fisher's exact t tests were utilized
- to determine statistical significance.
- 37 **Results:** Patients with ARS were found to have ILD in 51.9% of cases, which was comparable to the
- frequency of ILD in systemic sclerosis (59.5%). The severity of FVC reduction in ARS (53.2%) was
- 39 comparable to diffuse cutaneous systemic sclerosis (56.8%, p=0.48) and greater than dermatomyositis
- 40 (66.9%, p=0.005) or limited cutaneous systemic sclerosis (lcSSc, 71.8%, p=0.005). Frank
- 41 honeycombing was seen with ARS antibodies but not other myositis autoantibodies. ARS patients were
- more likely to first present to a pulmonary provider in a tertiary care setting (53.6%), likely due to fewer
- 43 extrapulmonary manifestations. Only 33% of ARS-ILD were anti-nuclear antibody, rheumatoid factor,
- or anti-cyclic citrullinated peptide positive. Patients with ARS-ILD had a two-fold longer median time to
- diagnosis compared to other myositis-ILD patients (11.0 months, IQR 8.5 to 43 months vs. 5.0 months,
- 46 IQR 3.0 to 9.0 months, p=0.003).
- 47 **Conclusions:** ARS patients without prominent extra-pulmonary manifestations are at high risk for not
- 48 being recognized as having a connective tissue disease related ILD and miscategorized as UIP/IPF
- 49 without comprehensive serologies.

- 51 Idiopathic inflammatory myopathies
- 52 Anti-tRNA synthetase syndrome
- 53 Systemic sclerosis
- 54 Connective tissue disease related interstitial lung disease
- Usual interstitial pneumonia

Recognition of idiopathic inflammatory myopathy (IIM) spectrum disease is challenging due phenotypic heterogeneity. While the original Bohan and Peter criteria focused on classic skin rashes and muscle weakness [1], there has been increasing recognition that these clinical classifications oversimplify marked heterogeneity and that myositis autoantibodies are associated with a variety of classical clinical presentations (table 1). Interstitial lung disease is particularly prevalent in the anti-tRNA synthetase syndrome (ARS), which classically presents with the triad of arthritis, interstitial lung disease, and mechanic's hands. Amongst ARS antibodies, however, the frequency of skin, muscle, and lung disease is variable. Patients with anti-Jo-1 antibodies are more likely to have joint and muscle involvement; non-Jo-1 positive patients are more likely to have vascular and cutaneous involvement [2]. Patients with anti-PL7 and anti-PL12 antibodies have more severe pulmonary manifestations [3].

The diagnosis of IIM-ILD remains a challenge. Presently, the American Thoracic Society recommends that CTD-ILD be ruled out clinically and with basic serologic screening (anti-nuclear antibodies (ANA), rheumatoid factor (RF), and anti-cyclic citrullinated antibodies (CCP)), but does not recommend comprehensive myositis serologies [4]. However, not only are basic serologies more apt to be negative in IIM compared other connective tissue diseases, but IIM patients are also less likely to fulfil clinical connective tissue disease (CTD) classification criteria. For example, nearly all patients with SSc-ILD will have a positive ANA, and the clinical classification criteria for SSc have >95% sensitivity in external validation cohorts [5]. In contrast, fewer than 50% of ARS patients have a positive ANA [6], and external validation of the 2017 American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) classification criteria for idiopathic inflammatory myopathies cohorts has yielded sensitivities as low as 71% [7]. For non-Jo1 associated ARS, the sensitivity of the 2017 ACR/EULAR classification criteria is as low as 25% [8]. This low sensitivity has led to the ACR/EULAR funding the CLASS (classification criteria of antisynthetase syndromes) project to develop improved criteria to diagnose of ARS [9].

The goal of this retrospective cohort study was to (1) evaluate the clinical, radiographic, and serologic features of ARS compared to other patients with IIM and SSc, and (2) gain insights into

possible etiologies leading to delayed diagnosis and therapy in the ARS subgroup. We hypothesize that ARS patients will have more subtle clinical and laboratory findings compared to other subsets of IIM-ILD and SSc-ILD despite an equivalent physiologic severity of ILD.

Patients and Methods

Patient Identification

Institutional Review Board approval was obtained. Patients were identified from either the Myositis and Scleroderma Treatment Initiative Center (MYSTIC) cohort or the ILD in Autoimmune Inflammatory Myopathy Cohort (IAIMC). Patients with suspected systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, or interstitial pneumonia with autoimmune features were eligible for referral to the MYSTIC cohort by their treating provider in the outpatient pulmonary, thoracic surgery, or rheumatology clinic, the inpatient rheumatology or pulmonary consulting service, or by their critical care provider in the intensive care unit (VUMC IRB 141415) from September 20, 2017-December 31, 2019. As MYSTIC is a longitudinal convenience cohort, additional patients were identified through the electronic medical record (VUMC IRB 180672) using a keyword search of the following: "dermatomyositis", "polymyositis", "anti-synthetase syndrome", "systemic sclerosis" in any Vanderbilt Rheumatology or Pulmonology affiliated practice visit between July 1, 2018-October 31, 2018. Exclusion criteria included prior inclusion in the MYSTIC cohort and myositis attributed to medications, infection, or another rheumatologic condition (e.g. mixed connective tissue disease. Diagnoses were verified by review of progress notes, laboratory findings, and scanned documents.

Clinical phenotyping

Clinical phenotyping was performed by chart abstraction to identify date of symptom onset, skin manifestations (digital ulceration/pitting, mechanic's hands, Gottron's sign/papules, heliotrope rash, shawl sign, skin ulcerations), Raynaud's phenomenon, inflammatory arthritis, pulmonary manifestations (ILD, pulmonary arterial hypertension), myocarditis, muscle weakness, esophageal dysmotility and/or

reflux. Serologic data collected included ANA titer and pattern, RF, anti-CCP, and comprehensive myositis serologies (Jo-1, PL-7, PL-12, EJ, OJ, SRP, Mi-2, P155/140, Tif-1γ, SAE1, MDA-5, NXP-2, Ro52, Ro60, Pm/Scl-100, U3RNP, U2RNP through ARUP, Salt Lake, UT). Data on cytoplasmic ANA antibodies was not routinely available. Laboratory values for creatinine kinase (CK) were recorded when available. Patients with dermatomyositis or polymyositis met the 2017 ACR/EULAR classification criteria for probable or definite dermato- or polymyositis [10]. Patient with ARS met the diagnostic criteria proposed by Connors et al. [11] but were not required to meet the 2017 IIM classification criteria. SSc patients met the 2013 classification criteria [12]. When documenting first point of contact at VUMC, patients presenting to thoracic surgery were classified as having presented to a pulmonary provider. Basic demographic data such as age, self-identified gender, and self-identified race/ethnicity were also collected.

121 Pulmonary phenotyping

Pulmonary phenotyping was performed using chart abstraction and analysis of computerized tomography (CT) scans, chest x-ray, PFTs, echocardiogram, right heart catheterization (RHC), and pathology reports. Patients were classified as having interstitial lung disease if the radiologist reading the clinical CT scan determined that fibrosis or interstitial lung disease was present on CT scan or chest x-ray if CT was unavailable. The severity of restriction or reduction in DLCO was graded as mild (65-79% predicted), moderate (50-64% predicted) or severe (<50% predicted) using the worst available PFT value. Patients were classified as having pulmonary hypertension if an echocardiogram demonstrated RVSP > 40 mmHg or mean PA pressure on RHC >25 mmHg. RHC was considered gold standard in cases of conflicting data. CT reports were analyzed for mention of honeycombing, bronchiectasis, or ground glass opacities. Radiographic classifications of ILD, e.g. usual interstitial pneumonia (UIP), atypical for UIP, nonspecific interstitial pneumonia (NSIP), and organizing pneumonia (OP) as determined by the reading radiologist was recorded. Patients for whom no CT or PFTs were obtained were assumed to have no or mild ILD [13, 14].

Statistics

All available cases were analyzed. Bias was minimized through blinding during chart abstractions. Missing data was addressed through pairwise deletion. Categorical variables were analyzed using Fisher's exact test through the GraphPad Quick Calcs Web site: http://www.graphpad.com/quickcalcs/ (accessed November 2020). Differences in continuous variables were tested using Kruskal-Wallis ANOVA for multiple comparisons followed by Mann-Whitney U tests for comparisons between groups in GraphPad Prism v.7.04. All analyses were two-tailed, and *p values* of less than 0.05 were considered statistically significant. Data is reported as the average ± standard error of the mean unless otherwise noted.

Results

Demographics

Demographic characteristics are shown in Table 2. One hundred twenty-five patients were included in the study; one patient was excluded due to conflicting historical reports regarding the presence of ILD and the lack of any PFTs or CT scans. Eighty-four patients (20 DM, 4 PM, 16 ARS, 14 dcSSc, 30 lcSSc) were included from the prospective MYSTIC cohort; 40 unique patients were included from electronic IAIMC cohort (17 DM, 8 PM, 12 ARS, 2 dcSSc, 1 lcSSc). Subjects were predominantly female (77.9% IIM, 78.7% SSc) and Caucasian (81.8% IIM, 78.7% SSc). Median disease duration was estimated from the first report of symptom onset to cohort enrolment and was 5.2 years for IIM versus 9.5 years in SSc (p=0.007).

Clinical phenotypes in IIM

Clinical characteristics of IIM patients are shown in Table 3. Thirty-seven patients (48.1%) were classified as DM, 12 (15.5%) were classified as PM, and 28 (36.4%) were diagnosed as ARS.

Subjective proximal muscle weakness was less common in ARS (64.3%) than PM (100%, p=0.002) but

not DM (73.0%, p=0.09). There was no difference in the frequency of muscle enzyme elevation in ARS (75.0%) compared to DM (78.3%, p=0.77) or PM (91.7%, p=0.40). Dysphagia or GERD was present in 46.4% of ARS patients, which was not statistically different from DM (29.8%, p=0.20) or PM (66.7%, p=0.31). Inflammatory arthritis was noted in 60.7% of ARS patients, which is higher than either DM (27.0%, p=0.01) or PM (8.3%, p=0.004). By convention, cutaneous manifestations are absent in polymyositis. There was a lower prevalence of Gottron's sign/papules or heliotrope rash in ARS compared to DM (21.4% v. 89.1%, p=0.0001). There was no difference in prevalence between ARS and DM of mechanic's hands (43.8% v. 24.3%, p=0.18) or Raynaud's phenomenon (37.8% v. 35.7%, p=1.0).

Known interstitial lung disease was present in 51.9% of IIM patients. Chest CT scans were available for all but two IIM-ILD patients. ILD was more frequently seen in ARS (78.5%) than in dermatomyositis (40.5%, p=0.00263) or polymyositis (25.0%, p=0.003). In this cohort, all patients with PL-7, PL-12, or EJ antibodies had interstitial lung disease; 80% of Jo-1 positive patients had ILD. Patients with Mi-2 associated dermatomyositis had the lowest frequency of ILD with only 20.0% having known ILD.

Serologically, only 36% of ARS patients were ANA positive compared to 80.6% of DM patients (p=0.004) and 60% of PM patients (p=0.45). Ro52 positivity was observed with similar frequency in ARS and DM (63.6% v.40.0%, p=1.00) but no PM patient was Ro52 positive. There was no statistically significant difference in the frequency of RF positivity.

Patients with ARS-ILD frequently present to pulmonary providers at a tertiary center

Of ARS patients, 53.6% presented first to pulmonary providers, which is significantly higher than DM (16.2%, p=0.003) or PM (8.3%, p=0.01). There was no difference in the likelihood of Jo-1 or non-Jo1 associated ARS to present first to a pulmonary provider (60.0% v. 75.0%, p=0.65). Of the 15 patients with ARS-ILD who presented initially to pulmonology, 80% of patients had been seen by outside pulmonologists and 40% by outside rheumatologists. Only one had received the correct

diagnosis of ARS-ILD prior to tertiary referral. The time from symptom onset to diagnosis could be abstracted for 21/22 ARS-ILD patients, 11/15 DM-ILD patients, and 3/3 PM-ILD patients. Patients with ARS-ILD had a longer median time to diagnosis (11.0 months, IQR 8.5 to 43 months) than other IIM-ILD subsets (5.0 months, IQR 3.0 to 9.0, p=0.003). (Figure 1) There was a trend towards ARS-ILD patients presenting to pulmonary clinic being less likely to meet IIM classification criteria, but this did not reach significance (66.7% v. 85.8%, p=0.6158).

Many pulmonary providers will screen for CTD-ILD using an ANA, RF, and anti-CCP antibodies. The efficacy of detecting a potential CTD-ILD with a basic serologic assessment using ANA, RF, and anti-CCP testing is shown in table 4. Patients with ARS-ILD were much less likely to be identified using this strategy than DM-ILD (33.3% v. 86.7%, p=0.002). If a CK was also obtained, the likelihood of detecting a possible CTD-ILD increased to 72.7% for ARS-ILD compared to 86.7% for DM-ILD (p=0.43). Statistical comparisons to PM-ILD were precluded due to small sample size. Myositis specific serologies were required to detect the final 27.3% of patients with ARS-ILD.

Radiographic features of ARS-ILD

Radiographic features of IIM and SSc associated ILD are shown in table 5. Due to the paucity of PM-ILD, these were excluded from statistical comparisons. Notably, only patients with anti-tRNA synthetase antibodies (22.7%) had CT scans that were read by a radiologist as compatible with usual interstitial pneumonia (UIP); no patient a non-anti-tRNA synthetase antibody had a CT scan compatible with UIP. The solitary patient with clinical dermatomyositis and a UIP pattern CT scan did not have comprehensive myositis serologies. Patients with UIP pattern CT scans ranged in age from 49.2 to 70.8 years of age and there was a trend towards the median age of UIP-pattern patients being older than non-UIP pattern patients (63.3, IQR 54.8,70.8 yrs., v. 55.2, IQR 46.8,60.6 yrs., p=0.09). Bronchiectasis trended towards being more prevalent in ARS compared to other IIM subsets (50% v. 22.2%, p=0.10). Of ARS patients, 13.6% had frank honeycombing, which was not seen an any other

IIM subset. There was no difference in the frequency of ground glass abnormalities between ARS and other IIM patients.

Physiologic features of ARS-ILD.

Physiologic features of IIM- and SSc- ILD are shown in Figures 2 and 3. Due to the paucity of PM patients with ILD, these were again excluded from subgroup statistical analyses. Overall, patients with IIM and SSc had comparable restriction (60.3% v. 66.6% predicted FVC, p=0.15) and diffusion impairment (48.0% v. 51.1% predicted DLCO, p=0.63). However, ARS-ILD demonstrated more severe reduction in FVC (53.2% predicted) than patients with DM (66.9% predicted, p=0.005) or IcSSc (71.8% predicted, p=0.005). The severity of ARS and dcSSc-ILD was comparable (53.2% v. 56.8% predicted FVC, p=0.48). Similarly, patients with ARS were more likely to have a severe diffusion impairment (e.g. <50% predicted) than in DM (54.5% v. 6.7%, p=0.004) but not dcSSc (54.5% v. 30.0%, p=0.27). While there was a trend towards worsening impairment of diffusion in ARS relative to DM (39.8% v. 48.0% predicted DLCO, p=0.08) and dcSSc (39.8% v. 51.4% predicted DLCO, p=0.13), this did not reach statistical significance. There was no difference in the severity of restriction or diffusion impairment ARS-ILD patients with positive vs. negative Jo-1 antibodies.

Discussion

Our primary findings can be summarized as following, (1) patients with ARS have a high frequency of interstitial lung disease with more severe restriction than other IIM subsets (2) radiographic UIP was observed only in patients with ARS-ILD in this cohort, (3) patients with ARS are frequently referred to a tertiary center after seeing a local pulmonologist and/or rheumatologist without receiving the correct diagnosis, and (4) patients with ARS-ILD have a delayed diagnosis compared to DM-ILD and PM-ILD. Improving recognition of ARS-ILD is key to ensuring these patients have prompt access to immunosuppressive therapies. Diagnostic delays in ARS are well described and are known to be an independent risk factor for mortality in ARS-ILD [2]. Cavagna et al. described Jo-1 positive patients

who presented without the classic triad of arthritis, myositis, and interstitial lung disease had a trend towards increased median time to diagnosis from 2.5 to 10 months [15]. While delays in ARS-ILD diagnosis are frequently discussed in the literature, to our knowledge this is the first report to quantify a delay in diagnosis in ARS-ILD compared to other IIM-ILD. Given that nearly 25% of ARS patients present first with ILD [2], decreasing the diagnostic delay is critical.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

The frequency with which ARS-ILD presents with UIP radiographically further complicates recognition of ARS-ILD. In our cohort, 22.7% of patients had CT scans read as compatible with UIP. While ARS-UIP may be enriched at an academic center, it has previously been recognized that most IIM-UIP is associated with ARS. Of the 43 patients in the Pittsburgh cohort with biopsy proven UIP, only one did not have ARS [16]. Using the 2013 Fleischner Society guidelines, a cohort of 69 Chinese ARS-ILD patients identified that 8.7% had a high resolution CT scan classified as UIP [17]. A second longitudinal study of serial CT scans in ARS-ILD found that while 100% of patients had some ground glass at diagnosis, subsequent scans showed the ground glass decreased in 38%. Additionally, 42% of patients had honeycombing and 50% had worsening traction bronchiectasis at follow-up [18]. The prevalence of honeycombing and traction bronchiectasis in ARS may lead to radiographic classification as UIP on CT scans, especially in the community setting. The 2018 American Thoracic Society guidelines for diagnosing idiopathic pulmonary fibrosis allow patients with ground-glass opacities to be classified as UIP in the absence of other clear etiologies and so long as the ground-glass opacities are not the predominant radiographic feature [4]. Thus, ARS patients without prominent extra-pulmonary manifestations are at high risk for not being recognized as having an alternative etiology and miscategorized as UIP/IPF in the absence of comprehensive serologies.

In our cohort, only 33% of patients were identified on basic screening serologies to have signs of a connective tissue disease. While this is slightly lower than some prior studies [6, 17], a substantial number of ARS patients are ANA, RF, and anti-CCP negative in all cohorts. Additionally, there is increasing evidence that obtaining comprehensive serologies and engaging rheumatology improves the care of ILD patients. Nakashima et al. evaluated the ARS serology status of 168 patients with

idiopathic interstitial pneumonia and found that 10.7% were positive for an anti-tRNA synthetase antibody, including 5.3% of patients who were diagnosed as IPF [19]. Another study found that even a modest expansion of routine serologies and inclusion of a rheumatologist in the multi-disciplinary ILD team resulted in 21% of IPF patients being re-classified as having an autoimmune process and eight invasive diagnostic procedures were avoided [20]. This study further highlights the importance of using expanded serologies to aid in the identification of IIM-ILD generally and ARS-ILD specifically.

Prompt recognition of ARS-ILD is imperative as immunosuppression is efficacious in ARS-ILD.

Previous work by Danoff and co-workers demonstrated that patients with IIM-ILD have an improvement in their FVC following treatment with immunosuppressive therapy [21]. A post-hoc analysis of the rituximab in myositis phase III clinical trial [22] indicated a benefit in ARS-ILD. Efficacy for tacrolimus in both naïve [23] and refractory IIM-ILD [24] has also been reported. Even patients with myositis related usual interstitial pneumonia, which is nearly always ARS-ILD, have a slower rate of FVC decline and improved mortality compared with IPF patients after treatment with immunosuppression [16]. However, if a patient is not recognized to have ARS-ILD, they may not gain access to critically needed immunosuppressive agents. For this reason, we continue to advocate for the use of comprehensive serologies in the evaluation of new patients with interstitial lung disease and the inclusion of rheumatologists as part of the multi-disciplinary team discussion of ILD patients.

This study has several limitations. First, a cross-sectional design at a single center resulted in a limited sample size, which precluded comparisons between some IIM-ILD groups. Additionally, not all CT scans used in this study were high-resolution, which is considered gold standard for the classification of ILD patterns. Further, the use of retrospective chart abstractions meant that not all patients had a complete dataset, and data on objective muscle weakness across the entire clinical course was not available. While comprehensive myositis serologies are clearly useful for identifying ARS-ILD, the yield of comprehensive myositis screening in a tertiary ILD clinic is unclear.

In conclusion, ARS patients without prominent extra-pulmonary manifestations are at high risk for not being recognized as having an alternative etiology and miscategorized as UIP/IPF in the absence of

comprehensive serologies. Future work is required to (1) quantify the benefit instituting comprehensive serologies and rheumatologic consultation in the care of ILD patients at a tertiary care center and (2) determine if obtaining comprehensive myositis serologies improves patient outcomes.

Acknowledgements: This work was supported by CTSA award No. UL1TR000445 (EMW) from the National Center for Advancing Translational Sciences, the National Institutes of Health T32HL087738 (EMW), T32AR0590139 (JJY), K08AR072757 (AB), Vanderbilt Faculty Research Scholars Award (EMW), and the Porter Family Fund for Autoimmunity Research. The contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

References

- 303 1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975:
- 304 292(7): 344-347.
- 305 2. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV. Patients with
- non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. *Ann*
- 307 Rheum Dis 2014: 73(1): 227-232.
- 308 3. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L,
- 309 Christopher-Stine L, Mammen AL, Danoff SK. A longitudinal cohort study of the anti-synthetase
- 310 syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and
- anti-PL12 autoantibodies. Rheumatology (Oxford) 2017: 56(6): 999-1007.
- 312 4. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V,
- Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK,
- Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL,
- Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson
- KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic
- Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care*
- 318 *Med* 2018: 198(5): e44-e68.
- 5. Hoffmann-Vold A-M, Gunnarsson R, Garen T, Midtvedt Ø, Molberg Ø. Performance of the 2013
- 320 American College of Rheumatology/European League Against Rheumatism Classification Criteria for
- 321 Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease.
- 322 The Journal of Rheumatology 2015: 42(1): 60-63.
- 323 6. Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis CV. A Negative Antinuclear Antibody
- Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening
- Test for Antisynthetase Syndrome. *J Rheumatol* 2017: 44(2): 223-229.

- 326 7. Luu Q, Day J, Hall A, Limaye V, Major G. External Validation and Evaluation of Adding MRI or
- 327 Extended Myositis Antibody Panel to the 2017 EULAR/ACR Myositis Classification Criteria. ACR Open
- 328 Rheumatology 2019: 1(7): 462-468.
- 329 8. Greco M, García de Yébenes MJ, Alarcón I, Brandy-García AM, Rúa-Figueroa Í, Loza E,
- Carmona L. Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of
- antisynthetase antibodies to improve current classification criteria. Annals of the Rheumatic Diseases
- 332 2019: 78(9): 1291-1292.
- 333 9. Knitza J, Cavagna L, Schett G, Distler JHW. Comment on: 'Idiopathic inflammatory myopathies
- and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification
- criteria' by Greco et al. Annals of the Rheumatic Diseases 2020: 79(7): e85-e85.
- 10. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA,
- Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K,
- Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA,
- Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A,
- 340 Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria
- Project consortium TEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017
- European League Against Rheumatism/American College of Rheumatology classification criteria for
- adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis*
- 344 2017: 76(12): 1955-1964.
- 11. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with
- the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? *Chest*
- 347 2010: 138(6): 1464-1474.
- 12. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M,
- Naden RP, Medsger TA, Jr., Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O,
- Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M,
- Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH,

- Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski
- 353 S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an
- 354 American College of Rheumatology/European League against Rheumatism collaborative initiative.
- 355 Arthritis Rheum 2013: 65(11): 2737-2747.
- 356 13. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in
- patients with interstitial lung disease. Chest 1999: 116(5): 1175-1182.
- 14. Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C. The
- Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary
- 360 fibrosis. Respir Med 2005: 99(6): 755-761.
- 15. Cavagna L, Nuno L, Scire CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castaneda S,
- 362 Sifuentes Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A,
- Saketkoo LA, Ortego-Centeno N, Quartuccio L, Bartoloni E, Specker C, Murcia TP, La Corte R, Furini
- F, Foschi V, Corral JB, Airo P, Cavazzana I, Martinez-Barrio J, Hinojosa M, Giannini M, Barsotti S,
- Menke J, Triantafyllias K, Vitetta R, Russo A, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C,
- Parisi S, Montecucco C, Gonzalez-Gay MA, group Ac. Clinical Spectrum Time Course in Anti Jo-1
- Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study.
- 368 Medicine (Baltimore) 2015: 94(32): e1144.
- 16. Aggarwal R, McBurney C, Schneider F, Yousem SA, Gibson KF, Lindell K, Fuhrman CR, Oddis
- 370 CV. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary
- 371 fibrosis. *Rheumatology (Oxford)* 2017: 56(3): 384-389.
- 17. Liu H, Xie S, Liang T, Ma L, Sun H, Dai H, Wang C. Prognostic factors of interstitial lung
- disease progression at sequential HRCT in anti-synthetase syndrome. *European Radiology* 2019:
- 374 29(10): 5349-5357.
- 18. Debray MP, Borie R, Revel MP, Naccache JM, Khalil A, Toper C, Israel-Biet D, Estellat C, Brillet
- PY. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. *Eur J Radiol*
- 377 2015: 84(3): 516-523.

- 19. Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M,
- Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K,
- Hisata S, Nukiwa T, Mimori T. The multicenter study of a new assay for simultaneous detection of
- multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. *PLoS One* 2014: 9(1):
- 382 e85062.
- 20. Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Koslow M, Shitrit D. Rheumatological
- Assessment Is Important for Interstitial Lung Disease Diagnosis. *The Journal of Rheumatology* 2018:
- 385 **45(11)**: **1509-1514**.
- 386 21. Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ,
- 387 Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK. Long-Term Treatment With Azathioprine and
- 388 Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. *Chest* 2019: 156(5): 896-906.
- 389 22. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider
- LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV. Predictors of clinical improvement in
- 391 rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis
- 392 Rheumatol 2014: 66(3): 740-749.
- 393 23. Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T,
- Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases
- complicated with polymyositis or dermatomyositis. *Rheumatology (Oxford)* 2015: 54(1): 39-44.
- 396 24. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of
- 397 antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis & Rheumatism: Official
- Journal of the American College of Rheumatology 2005: 52(8): 2439-2446.
- 399 25. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY,
- Tiev KP, Vittecoq O, Noel D, Mouthon L, Menard JF, Jouen F. Comparison of long-term outcome
- between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. *Autoimmunity*
- 402 Reviews 2012: 11(10): 739-745.

- 403 26. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-
- isoleucyl-tRNA synthetase) autoantibodies. *Rheumatology* 2007: 46(5): 842-845.
- 405 27. Carlos de Souza FH, Pina Cruellas MG, Levy-Neto M, Shinjo SK. Anti-synthetase syndrome:
- anti-PL-7, anti-PL-12 and anti-EJ. Revista Brasileira de Reumatologia (English Edition) 2013: 53(4):
- 407 352-357.
- 408 28. Giannini M, Notarnicola A, Dastmalchi M, Lundberg IE, Lopalco G, Iannone F. Heterogeneous
- 409 clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case
- 410 series. *Clinical Rheumatology* 2016: 35(9): 2363-2367.
- 411 29. Schneider F, Yousem SA, Bi D, Gibson KF, Oddis CV, Aggarwal R. Pulmonary pathologic
- manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. *Journal of*
- 413 *Clinical Pathology* 2014: 67(8): 678-683.
- 414 30. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramírez R, Jara LJ, Saavedra MA, Cruz-
- Gonzalez C, Andrade-Ortega L, Vera-Lastra O, Salazar-Páramo M, Prieto-Parra RE, Gonzalez-Lopez
- L, Gamez-Nava JI, Ramírez-Sánchez HU, Chan JYF, Ross SJ, Chan EKL, Vázquez-Del Mercado M.
- 417 Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two
- dermatomyositis cohorts from Mexico City and Guadalajara. *Arthritis Research & Therapy* 2013: 15(2):
- 419 R48.
- 420 31. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK,
- Johnson C, Christopher-Stine L, Mammen AL. Antinuclear Matrix Protein 2 Autoantibodies and Edema,
- Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. *Arthritis Care & Research* 2017:
- 423 69(11): 1771-1776.
- 424 32. Yang H, Lu X, Peng Q, Jiang W, Shi J, Zhang Y, Chen H, Wang G. Differential Clinical
- 425 Associations of Anti–Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory
- 426 Myopathies. *Arthritis & Rheumatology* 2018: 70(8): 1288-1297.
- 427 33. Cuesta-Mateos C, Colom-Fernández B, Portero-Sainz I, Tejedor R, García-García C, Concha-
- 428 Garzón MJ, De las Heras-Alonso ME, Martínez MA, Juarez C, Muñoz-Calleja C. Autoantibodies against

- TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical
- significance and diagnostic utility. *Journal of the European Academy of Dermatology and Venereology*
- 431 2015: 29(3): 482-489.
- 432 34. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, McHugh NJ.
- 433 Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small
- 434 ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-
- onset myositis. Annals of the Rheumatic Diseases 2009: 68(10): 1621-1625.
- 436 35. Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik JJ, Danoff SK, Casciola-Rosen L,
- Christopher-Stine L, Mammen AL. Longitudinal Course of Disease in a Large Cohort of Myositis
- Patients With Autoantibodies Recognizing the Signal Recognition Particle. *Arthritis Care & Research*
- 439 2017: 69(2): 263-270.
- 440 36. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma Differentiation-
- 441 associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with
- Dermatomyositis. *The Journal of Rheumatology* 2017: 44(3): 319-325.
- 443 37. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airò P, Cattaneo R, Franceschini F.
- Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. *Lupus*
- 445 2008: 17(8): 727-732.
- 446 38. Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L,
- Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL. Muscular and extramuscular
- features of myositis patients with anti-U1-RNP autoantibodies. *Neurology* 2019: 92(13): e1416-e1426.
- 449 39. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger Jr. TA. Anti-U3 RNP autoantibodies in
- 450 systemic sclerosis. *Arthritis & Rheumatism* 2009: 60(4): 1112-1118.
- 451 40. De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C, Milisenda JC,
- Casal-Dominguez M, Corse AM, Danoff SK, Christopher-Stine L, Paik JJ, Mammen AL. Muscular and
- extramuscular clinical features of patients with anti-PM/Scl autoantibodies. *Neurology* 2018: 90(23):
- 454 e2068-e2076.





Figure 1. Time to diagnosis for patients with ARS-ILD (n=21) compared to DM/PM-ILD (n=14). Violin plots show the range with interquartile range. Mann-Whitney U-tests shown.






Figure 2. Physiologic features of IIM-ILD comparaed to SSc-ILD. (A) Patients with ARS have more severe restriction than DM or IcSSc and similar restriction compared to dcSSc. (B) There is no significant difference in diffusion impairment amongst IIM or SSc subsets. Box plots depict median ± IQR, KW=Kruskal-Wallis, Mann-Whitney U-test *p<0.05, **p<0.01.




Figure 3. Stratification of physiologic impairment according to American Thoracic Society criteria. The severity of impairment of (A) FVC and (B) DLCO for IIM and SSc subsets are shown.

Table 1. Clinical manifestations of various myositis specific and associated autoantibodies

	Autoantibody	Clinical features	Frequency of organ involvement			
			Skin	Muscle	Lung	
Λοά: 4DNA	Jo-1[3, 25]	Classic dermatomyositis with typical rash, muscle weakness, ILD, and mechanic's hands	30-58%	69.3-86%	68%-95%	
Anti-tRNA	PL-7 [3, 25]		29-56%	40-81%	>90%	
synthetase syndrome	PL-12 [3, 25]	Hypomyopathic myositis with frequent arthritis,	29-70%	40-69%	>90%	
Syndroine	OJ [26]	mechanic's hands, and ILD	0%	57%	100%	
	EJ [27-29]		0-75%	0-100%	50-100%	
	Mi-2 [30]	Classical rash with mild to moderate muscle involvement, ILD uncommon	90%	100%	7%	
Other myositis specific autoantibodies	NXP-2 [31, 32]	Mild to moderate muscle involvement with myalgia, dysphagia, classical skin rashes, increased malignancy risk, can be associated with ILD	17-32%	>95%	7-25%	
	ΤΙF-1γ [33]	Marked skin involvement often with ulceration, muscle weakness, dysphagia, malignancy	>90%	63%	9.1%	
	SAE [34]	Classic skin rashes associated with mild to moderate weakness, ILD uncommon	>80%	>95%	18%	
	SRP [35]	Necrotizing myopathy with marked weakness, minimal skin involvement, and infrequent ILD	3%	>90%	22%	
	MDA5 [36]	Frequent and severe ILD with minimal or no muscle involvement and classically ulcerative skin lesions or palmar papules.	87.5%	50%	50%	
Overlap syndrome autoantibodies	Ku [37]	Overlap syndrome of systemic sclerosis and inflammatory myositis with mild muscle/skin involvement and variable ILD severity	n.r.	30%	43%	
	U1RNP [38]	Overlap syndrome of systemic lupus, systemic sclerosis, and inflammatory myositis	60%	80%	45%	
	U3RNP [39]	Diffuse systemic sclerosis with increased frequency of inflammatory myopathy	>95%	25%	61%	
	Pm/Scl [40]	Mild myositis and/or systemic sclerosis features frequently with ILD	85%	38%	61%	

*ILD more common in patients with inflammatory myositis compared to other Ku positive patients

Table 2. Demographics

	Idiopathic Inflammatory	Systemic Sclerosis	p value
	Myopathies (n=77)	(n=47)	
Age (years) [†]	57.7(48.4,66.7)	62.3(52.3,69.0)	.0.13
Female Gender	60 (77.9%)	37 (78.7%)	1.00
Race			
Caucasian	63 (81.8%)	37 (78.7%)	0.82
African American	11 (14.2%)	7 (14.9%)	1.00
Other	3 (3.9%)	3 (6.4%)	0.67
Disease Duration (years) [†]	5.2(2.4,10.4)	9.5(4.8,14.6)	0.007
Known Presence of ILD	40 (51.9%)	28 (59.5%)	0.46
Radiographic and physiologic evidence of ILD	33/40 (82.5%)	20/28 (71.4%)	0.37
Radiographic evidence of ILD with normal	2/40 (5.0%)	1/28 (3.6%)	1.00
PFTs			
Physiologic evidence of ILD with normal	5/40 (12.5%)	6/28 (21.4%)	0.34
imaging			
Historic documentation without objective data	0/40	1/28 (3.6%)	1.00
Known Presence of Pulmonary Hypertension	8 (20%)	17 (36.1%)	0.001
Pulmonology as First Point of Care at VUMC	22 (28.5%)	13 (27.6%)	1.00

[†]reported as median (interquartile range)

Abbreviations: ILD=interstitial lung disease, PFTs=pulmonary function tests, VUMC=Vanderbilt University Medical Center

Table 3. Clinical Phenotype of Idiopathic Inflammatory Myopathies Patients

									Dysphagia	Raynaud's
	Associated Serologies		Cutaneous Ma	Cutaneous Manifestations		Muscle Involvement		or GERD	Phenomenon	
				Gottron's or		Proximal	Muscle			
				Heliotrope	Mechanic's	Muscle	Enzyme			
	ANA	RF	Ro52	Rash	Hands	Weakness	Elevation			
By Clinical										
Phenotype*										
Dermatomyositis	25/31	4/17	8/12	33/37	9/37	27/37	29/37	10/37	11/37	14/37
(n=37)	(80.6%)	(23.5%)	(40.0%)	(89.1%)	(24.3%)	(73.0%)	(78.3%)	(27.0%)	(29.8%)	(37.8%)
Polymyositis	6/10	2/5	0/6	0/12	0/12	12/12	11/12	1/12	8/12	2/12
(n=12)	(60.0%)	(40.0%)	(0%)	(0%)	(0%)	(100%)	(91.7%)	(8.3%)	(66.7%)	(16.7%)
Anti-Synthetase	9/25	4/21	14/22	6/28	12/28	18/28	21/28	17/28	13/28	10/28
Syndrome	(36.0%)	(19.0%)	(63.6%)	(21.4%)	(43.8%)	(64.3%)	(75.0%)	(60.7%)	(46.4%)	(35.7%)
(n=28)										
By Serology										
Jo-1	3/11	2/10	5/9	2/14	8/14	12/14	12/14	13/14	7/14	6/14
(n=14)	(27.2%)	(20%)	(55.6%)	(14.3%)	(57.1%)	(85.6%)	(85.6%)	(92.9%)	(50%)	(42.9%)
PL-7	2/5	1/5	3/5	1/5	2/5	2/5	2/5	1/5	3/5	1/5
(n=5)	(40.0%)	(20.0%)	(60.0%)	(20.0%)	(40.0%)	(60.0%)	(40.0%)	(20.0%)	(60.0%)	(20.0%)
PL-12	1/5	1/4	4/6	3/6	1/1	3/6	5/6	1/6	3/6	2/6
(n=6)	(20.0%)	(14.3%)	(42.9%)	(50.0%)	(16.7%)	(50.0%)	(83.3%)	(16.7%)	(50.0%)	(33.3%)
EJ	0/1	0/0	1/1	0/1	0/1	0/1	1/1	1/1	1/1	0/1
(n=1)	(0%)	(0%)	(100%)	(0%)	(0%)	(0%)	(100%)	(100%)	(100%)	(0%)
OJ	1/2	0/0	1/1	0/2	1/2	1/2	1/2	1/2	1/2	1/2
(n=2)	(50.0%)	(0%)	(100%)	(0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)	(50.0%)
Ku	2/2	0/1	2/2	1/2	0/2	1/2	2/2	0/2	1/2	0/2

(n=2)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(50.0%)	(100%)	(0%)	(50.0%)	(0%)
NXP	3/3	0/2	1/2	2/3	0/3	2/3	3/3	0/3	1/3	0/3
(n=3)	(100%)	(0%)	(50.0%)	(66.7%)	(0%)	(66.7%)	(100.0%)	(0%)	(33.3%)	(0%_
TIF1g	1/1	0/0	0/1	1/1	0/1	1/1	1/1	0/1	1/1	0/1
(n=1)	(100%)	(0%)	(0%)	(100%)	(0%)	(100%)	(50.0%)	(0%)	(100%)	(0%)
Pm/Scl	4/4	2/2	2/4	3/4	3/4	4/4	4/4	2/4	3/4	0/4
(n=4)	(100%)	(100%)	(50.0%)	(75.0%)	(75.0%)	(100%)	(100%)	(50.0%)	(75.0%)	(0%)
SRP	0/2	0/1	0/2	0/2	0/2	2/2	2/2	0/2	2/2	0/2
(n=2)	(0%)	(0%)	(0%)	(0%)	(0%)	(100%)	(100%)	(0%)	(100%)	(0%)
Mi2	5/5	0/1	1/3	5/5	2/5	5/5	5/5	1/5	1/5	3/5
(n=5)	(100%)	(0%)	(33.3%)	(100%)	(40.0%)	(100.0%)	(10.0%)	(20%)	(20%)	(40%)

^{*}These are non-overlapping phenotypes. All patients with anti-tRNA synthetase antibodies were categorized as anti-synthetase syndrome.

Abbreviations: ANA=anti-nuclear antibodies, RF=rheumatoid factor, GERD=gastroesophageal reflux disease

Table 4. Comprehensive myositis serologies play a critical role in the serologic detection of ARS-ILD compared to other IIM-ILD

				Diagnostic yield after	Diagnostic yield after	Diagnostic yield after
	+ANA	+RF	+CCP	initial serologic work-up	testing CK level	adding MSA/MAA [†]
Dermatomyositis	11/12	3/6	2/4	13/15	13/15	13/15
(n=15)	(86.7%)	(50.0%)	(50.0%)	(86.7%)	(86.7%)	(86.7%)
Polymyositis	1/3	1/3	1/2	1/3	3/3	3/3
(n=3)	(33.3%)	(33.3%)	(50%)	(33.3%)	(100%)	(100%)
Anti-synthetase	5/20	4/18	0/13	7/21	16/22	22/22
Syndrome	(25.0%)	(22.2%)	(0%)	(33.3%)	(72.7%)	(100%)
(n=22)						

[†] MSA = myositis specific antibodies (Jo-1, PL-7, PL-12, OJ, EJ, Mi-2, SRP, TIF-1γ, MJ/NXP-2, SAE, MDA-5/CADM-140; MAA = myositis associated antibodies (Pm/Scl, Ku, U1RNP, U3RNP, Ro52)

Abbreviations: ARS-ILD=anti-tRNA synthetase related interstitial lung disease, IIM-ILD idiopathic inflammatory myopathies associated interstitial lung disease, ANA=anti-nuclear antibodies, RF=rheumatoid factor, CCP=anti-cyclic citrullinated peptide, CK=creatinine kinase,

Table 5. Radiographic features of interstitial lung disease in patients with IIM compared to SSc

	Radiographic Characteristics									
	UIP	GGO	ВС	HC						
Inflammatory My	ositis									
Dermatomyositis	1/13	10/13	4/13	1/13						
(n=15)	(7.7%)	(76.9%)	(30.8%)	(7.7%)						
Polymyositis	0/3	2/3	0/3	0/3						
(n=3)	(0%)	(66.7%)	(0%)	(0%)						
Anti-Synthetase	5/22	12/22	11/22	3/22						
Syndrome	(22.7%)	(54.5%)	(50%)	(13.6%)						
(n=22)										
By Serology										
Jo-1	2/10	9	7/10	12						
(n=10)	(20%)	(90%)	(70.0%)	(20.0%)						
PL-7	1	3	4	3						
(n=5)	(20%)	(60%)	(80%)	(60%)						
PL-12	1	4	4	1						
(n=5)	(20.0%)	(80%)	(80%)	(20%)						
EJ	0	0	0	0						
(n=1)	(0%)	(0%)	(0%)	(0%)						
OJ	0	1	0	0						
(n=1)	(0%)	(100%)	(0%)	(0%)						
Ku	0	1/2	0	0						
(n=2)	(0%)	(50%)	(0%)	(0%)						
NXP	0	1	1	0						
(n=1)	(0%)	(100%)	(100%)	(0%)						
Pm/Scl	0	3/3	1/3	0						
(n=3)	(0%)	(100%)	(33.3%)	(0%)						
SRP	0	0	0	0						
(n=1)	(0%)	(0%)	(0%)	(0%)						
Mi2	0	1	1	0						
(n=1)	(0%)	(100%)	(100%)	(0%)						
Systemic Scleros	sis	Systemic Sclerosis								

lcSSc	3/15	9/15	8/15	5/15
(n=18)	(20%)	(60%)	(53.3%)	(33.3%)
dcSSc	1/9	8/9	6/9	5/9
(n=10)	(11.1%)	(88.9%)	(66.7%)	(55.6%)

Abbreviations: IIM=idiopathic inflammatory myopathies,

SSc=systemic sclerosis, UIP = usual interstitial pneumonia (definite or probable), GGO = ground glass opacities, BC = bronchiectasis, HC = honeycomb changes, lcSSc=limited cutaneous systemic sclerosis, dcSSc=diffuse cutaneous systemic sclerosis